Voleon Capital Management LP Acquires Shares of 79,909 Pfizer Inc. (NYSE:PFE)

Voleon Capital Management LP bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 79,909 shares of the biopharmaceutical company's stock, valued at approximately $2,120,000.

Other hedge funds have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer during the 4th quarter valued at $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer in the fourth quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the 4th quarter worth about $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer during the 4th quarter valued at $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock traded down $0.23 during trading on Monday, reaching $23.98. 9,999,006 shares of the company's stock were exchanged, compared to its average volume of 40,372,634. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The firm's fifty day moving average price is $24.34 and its 200-day moving average price is $25.73. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $135.97 billion, a PE ratio of 17.00, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the prior year, the firm earned $0.82 EPS. The business's revenue was down 7.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.17%. Pfizer's dividend payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PFE shares. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.